1. Introduction {#sec1}
===============

Acute kidney injury (AKI) is a major and severe complication following orthotopic liver transplantation and is associated with poor graft survival and increased mortality \[[@B1], [@B2]\]. The incidence of AKI after liver transplantation (LT) is high and ranges from 20 to 64% \[[@B1], [@B3]--[@B8]\].

Currently, there is no effective therapy or preventive strategy available for AKI after LT \[[@B9]\], although several promising strategies have been investigated \[[@B10]--[@B12]\]. Therefore, to predict the occurrence of AKI after LT and treat AKI as early as possible will significantly improve the outcome of liver transplantation.

Although a number of studies have evaluated AKI after LT, the clinical risk factors, especially intraoperative risk factors, still need to be further explored. Most of the studies reported risk factors of AKI after LT including longer anhepatic phase \[[@B13]\], larger red blood cell (RBC) transfusion amount \[[@B5], [@B14]\], and higher Child-Turcotte-Pugh (CTP) score \[[@B15]\]. In addition, some hemodynamic factors such as intraoperative mean arterial blood pressure \[[@B16]\], the use of intraoperative venovenous bypass technology \[[@B17]\], central venous pressure, right ventricular end-diastolic volume, and mixed venous oxygen saturation \[[@B6]\] have been reported to significantly influence the occurrence of postoperative AKI.

Twenty-five percent of the cardiac output flows through the liver, and hepatic blood inflow (HBI) changes will influence systemic hemodynamics \[[@B18]\]. However, whether intraoperative HBI including hepatic artery flow (HAF) and portal vein flow (PVF) following reconstruction has a correlation with AKI following LT is unknown.

Therefore, the aim of this study was to investigate the relationship between HBI and early acute kidney injury (EAKI) after DCD LT as well as develop and validate a prediction model for EAKI after DCD LT using preoperative and intraoperative factors including HBI.

2. Materials and Methods {#sec2}
========================

2.1. Design and Patients {#sec2.1}
------------------------

This retrospective observational study was approved by the institutional review board of our institution (the First Hospital of China Medical University). We retrospectively reviewed the electronic medical records of 156 consecutive adult patients who underwent DCD LT at our institution between April 2005 and March 2017. The need for informed consent was waived given the study\'s retrospective design. Patients without complete intraoperative hepatic blood flow data or postoperative serum creatinine monitoring data were excluded (n = 15). Patients with renal replacement therapy (RRT) were excluded (n = 1). Patients who underwent combined liver-kidney transplantation (n = 2) or died within 48 hours postoperatively (n = 5) were excluded. Patients with perirenal hematoma after LT (n=1) were excluded. The remaining 132 patients were analyzed. Then, 105 patients were selected from April 2005 to March 2015 to form the development cohort of this study. The remaining 27 patients from April 2015 to March 2017 were evaluated to form a validation cohort.

2.2. Definition of EAKI {#sec2.2}
-----------------------

AKI was defined according to the KDIGO criteria \[[@B19]\]: an increase in serum creatinine by 0.3 mg/dL ( ≥26.5 *μ*mol/L) within 48 hours or an increase in creatinine to ≥ 1.5 times baseline within the first 7 postoperative days, which have been validated in patients undergoing LT \[[@B6], [@B7], [@B20]\]. We determined postoperative early acute kidney injury (EAKI) according to the KDIGO criteria mentioned above during 7 days of postoperative follow-up. A urine output criterion was not used. All patients who met the KDIGO criteria within 7 days after LT were classified as having EAKI.

2.3. Intraoperative Hepatic Blood Flow Monitoring {#sec2.3}
-------------------------------------------------

Our center used Transonic HT313 Flowmeter (Ithaca, New York, USA) to measure the reconstructed HAF and PVF before abdominal closure. The HAF is the sum of the mean blood flow of reconstructed hepatic arteries. The PVF represents intraoperative mean portal vein flow. The HBI is the sum of HAF and PVF.

2.4. Statistical Analysis {#sec2.4}
-------------------------

### 2.4.1. Patient Characteristics {#sec2.4.1}

The Shapiro test was used to determine the normality of the data. Either Fisher\'s exact test or *χ*^2^ test was used to compare the categorical variables between EAKI and non-EAKI patients. Comparisons of continuous variables between EAKI and non-EAKI patients were performed with Student\'s T tests or Mann-Whitney U tests.

### 2.4.2. Prediction Model Building {#sec2.4.2}

The Least Absolute Shrinkage and Selection Operator (LASSO) regression \[[@B21]\] was used to select predictors and eliminate multicollinearity. Logistic regression was used to identify univariate and multivariate predictors for EAKI. Model A was developed in the development cohort by multivariable logistic regression whose variables were selected by LASSO regression based on the one standard error criteria \[[@B22]\]. Model B is a simplified model of model A.

### 2.4.3. Models Evaluation {#sec2.4.3}

Calibration of the models was assessed using Hosmer-Lemeshow goodness-of-fit statistics. To evaluate the prediction performance of the models, the Harrell\'s concordance index (C-index) was measured in both the development and validation cohort. A calibration curve was plotted to compare the agreement between observed outcomes (Y-axis) and the predictions of the model (X-axis). Finally, to facilitate calculation of individualized risk in clinical practice, model B was converted to an easy-to-use nomogram.

### 2.4.4. Software {#sec2.4.4}

R software (Version 3.5.1, <http://www.r-project.org>) was used for the statistical analysis and plot generation, with rms, foreign, pROC, psych, glmnet, and ResourceSelection packages. P \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

Patient demographics and perioperative variables according to the diagnosis of EAKI are presented in [Table 1](#tab1){ref-type="table"}. EAKI occurred in 31 patients (29.5%) in the development cohort. There were significant differences in liver tumor (p=0.027), preoperative total bilirubin level (p=0.003), preoperative MELD score (p=0.015), preoperative CTP score (p=0.003), cold ischemic time (CIT) (p=0.028), operation time (OT) (p=0.015), anhepatic phase (AP) (p=0.002), packed red blood cell (pRBC) transfusion (p=0.005), cryoprecipitate transfusion (p=0.035), PVF (p=0.015), and HBI (p=0.015) between EAKI and non-EAKI patients in the development cohort. However, for HAF, there was no significant difference (p=0.905) between EAKI and non-EAKI patients.

3.2. Prediction Model Building {#sec3.2}
------------------------------

As shown in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, all continuous and categorical variables in the development cohort were performed by LASSO regression analysis using 10-fold cross-validation and the one standard error criterion. When parameter *λ* corresponds to the minimum-deviance within one standard error, 6 variables including CTP score, CIT, AP, HBI/h, OT, and pRBC transfusion were obtained. Then, the 6 variables were selected to build model A using multivariable logistic regression. Model B, a simplified model of model A, was built via eliminating CIT (p=0.211) and OT (p=0.212) from model A ([Table 2](#tab2){ref-type="table"}). After the Hosmer-Lemeshow test, model A and model B were a good fit for the data ([Table 3](#tab3){ref-type="table"}). The two prediction models can be shown in the following equations.

*Model A* $$\begin{matrix}
{P_{EAKI} = 1 - \frac{1}{e^{- 6.9 + 0.29 \times CTPscore + 0.3 \times {{CIT}/100} + 0.16 \times {{AP}/10} - 0.28 \times HBI/h + 0.37 \times {{OT}/100} + 0.19 \times {{pRBC}/1000}}}} \\
\end{matrix}$$

*Model B* $$\begin{matrix}
{P_{EAKI} = 1} \\
{\mspace{1800mu} - \frac{1}{e^{- 4.42 + 0.26 \times CTPscore + 0.27 \times {{AP}/10} - 0.26 \times HBI/h + 0.21 \times {{pRBC}/1000}}}} \\
\end{matrix}$$P~EAKI~: probability of postoperative EAKI occurrence.

3.3. Prediction Model Performance Assessment {#sec3.3}
--------------------------------------------

The receiver operating characteristic (ROC) curves of model A and model B in the development and validation cohort were shown in [Figure 2](#fig2){ref-type="fig"}. In the development cohort, the C-indexes of model A and B were 0.847 \[95% confidence interval (CI), 0.765-0.928\] and 0.823 \[95% CI, 0.738-0.908\], respectively, and there was no significant difference (p = 0.167, DeLong\'s test) in the C-indexes between the two models. In the validation cohort, the C-indexes of model A and B were 0.921 \[95% CI, 0.809-1.000\] and 0.921 \[95% CI, 0.816-1.000\], respectively, and there was no significant difference (p = 1.000, DeLong\'s test) in the C-indexes between the two models ([Table 4](#tab4){ref-type="table"}). The calibration curves of models were shown in [Figure 3](#fig3){ref-type="fig"}, and slopes of mode A in the development cohort and validation cohort were 1.000 and 1.830, respectively. Slopes of mode B in the development cohort and validation cohort were 1.000 and 2.056. Finally, the nomograms of model B were shown in [Figure 4](#fig4){ref-type="fig"}.

4. Discussion {#sec4}
=============

In this retrospective observational study, we made two important clinical findings. First, the HBI/h was a key risk factor in EAKI occurrence after DCD LT. Second, the prediction models combining with the HBI/h and other clinical parameters could accurately predict EAKI occurrence after DCD LT and had clinical value.

A previous study has reported that predictors for postoperative late acute renal failure (ARF) differ from early ARF and correspond to postoperative parameters \[[@B23]\]. Therefore, we built prediction models using preoperative and intraoperative parameters to predict postoperative early AKI.

AKI after LT is multifactorial in origin. Higher CTP score \[[@B15]\], longer cold ischemic time\[[@B24]\], longer anhepatic phase \[[@B13]\], longer operation time \[[@B1]\], and larger pRBC transfusion amount \[[@B5], [@B14]\] have been reported as high-risk factors or predictors of AKI after living-donor or cadaveric LT.

Higher MELD scores or CTP scores suggest worse pretransplant liver reservation function. And a higher MELD score may suggest worse pretransplant kidney function, either. Many studies have shown an association between preoperative MELD score and postoperative AKI \[[@B1], [@B4], [@B13]\]. In our study, MELD score was eliminated and CTP score was selected by LASSO regression; this might because there was no significant difference in baseline renal function between EAKI and non-EAKI patients.

Hepatic ischemia-reperfusion injury (HIRI) plays a critical role in the pathogenesis of AKI after LT \[[@B25]\]. HIRI is associated with a systemic inflammatory response, which may cause AKI through hemodynamic mechanisms and direct tubular cell death \[[@B26]\]. Thus, long warm ischemic time (WIT) and CIT will increase the probability of postoperative AKI theoretically. WIT had been considered as a key predictor of AKI following LT \[[@B7], [@B8]\]. But there was no significant difference (p=0.623) in WIT between EAKI and non-EAKI patients because WIT was strictly controlled in our center. CIT as a risk factor of AKI after LT remains controversial \[[@B7], [@B24]\]; this may be because different donor criteria or different cold storage conditions were used in different centers. In our study, there was no significant difference (p=0.883) in CIT between EAKI and non-EAKI patients in the validation cohort. So CIT as a predictor of EAKI needs to be reevaluated using a larger sample size in the future.

Systemic hemodynamic changes after LT are the cause of postoperative AKI \[[@B27]\]. Longer anhepatic phase, longer operation time, and larger pRBC transfusion all influence systemic hemodynamics and then influence renal blood perfusion. HBI accounts for about 25% of cardiac output \[[@B18]\] and HBI will change more or less after blood vessel reconstruction in LT. Our study suggested EAKI was relevant to HBI and PVF. Interestingly, after eliminating multicollinearity in LASSO regression, HBI/h was selected into prediction models, but how HBI influence renal blood flow needs to be investigated in future research.

Studies have shown that the incidence of ARF after classic orthotopic LT is significantly higher than that of ameliorative piggyback liver transplantation (APBLT) \[[@B27]\]. In this study, APBLT was performed in DCD LT.

This study has limitations. First, although our prediction model satisfies the minimum sample size requirement \[[@B28]\], the larger sample size is needed to verify the accuracy of the prediction model. Second, the models should be validated prospectively at other centers to demonstrate its applicability, however, there is no HBI data from other centers could be available in present. Third, during LT, we did not directly monitor cardiac output and kidney flow which would reflect perfusion of kidney and predict postoperative EAKI better. In addition, severe stages of EAKI were not analyzed because of the small sample size.

5. Conclusion {#sec5}
=============

In this study, we demonstrated that HBI can be a reliable predictor of EAKI after DCD LT for the first time. In addition, we developed an easy and accurate prediction model including CTP score, AP, HBI/h and pRBC transfusion for EAKI after DCD LT.
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The csv file is the anonymous data set of patients.

###### 

Click here for additional data file.

![EAKI predictors screened in the development cohort using LASSO regression. (a) Selection of tuning parameter (*λ*) in the LASSO regression via 10-fold cross-validation in the development cohort. Binomial deviances from the LASSO regression\'s cross-validation procedure were plotted as a function of log(*λ*). *λ* is the tuning parameter. Y-axis indicates binomial deviances. The lower x-axis indicates log(*λ*). Numbers along the upper x-axis represent the average number of predictors. Red dots indicate average deviance values for each model with given *λ*, and vertical bars through the red dots show the upper and lower values of the deviances. The vertical black lines define the optimal values of *λ*, where the model provides its best fits to the data. Lambda.min corresponds to the *λ* which minimizes mean squared error and was used for variable selection. Lambda.1se corresponds to the *λ* that is one standard error from the lambda.min. (b) LASSO coefficients produced by the regression analysis (in (a)). A vertical line at x-axis with log (*λ*) = -2.434 was generated based on the one standard error criteria in 10-fold cross-validation procedure. The 6 resulting predictors with nonzero coefficients were indicated in the plot.](BMRI2019-4572130.001){#fig1}

![ROC curves for prediction of EAKI by the models. (a) Development cohort. The C-index of each model is 0.847 \[95% CI, 0.765-0.928\] in model A; 0.823 \[95% CI, 0.738-0.908\] in model B. (b) Validation cohort. The C-index of each model is 0.921 \[95% CI, 0.809-1.000\] in model A; 0.921 \[95% CI, 0.816-1.000\] in model B.](BMRI2019-4572130.002){#fig2}

![Calibration curves of models. (a-d) A calibration curve was plotted to compare the agreement between observed outcomes (Y-axis) and the predictions of the model (X-axis). (a) Calibration curves of model A in the development cohort. (b) Calibration curves of model A in the validation cohort. (c) Calibration curves of model B in the development cohort. (d) Calibration curves of model B in the validation cohort.](BMRI2019-4572130.003){#fig3}

![The nomogram of model B for predicting incidence of EAKI following DCD LT. CTP score, Child-Turcotte-Pugh score; AP, anhepatic phase, min; pRBC, packed red blood cells transfusion, ml; HBI/h, hepatic blood inflow indexed by height, ml/min/cm. Draw an upward vertical line to the "Points" bar to calculate points. Based on the sum, draw a downward vertical line from the "Total Points" line to calculate EAKI possibility after DCD LT.](BMRI2019-4572130.004){#fig4}

###### 

Patients characteristics and perioperative parameters by KDIGO classification.

  *Characteristics*                         *Development cohort (n=105)*   *Validation cohort (n=27)*                                                                       
  ----------------------------------------- ------------------------------ ---------------------------- ---------------- ------------------------- ------------------------ -------
  *Demographic data*                                                                                                                                                         
   Age, years                               50 \[43-57\]                   53 \[48-58\]                 0.066            48 \[42-53\]              52 \[45-60\]             0.458
   Female, n                                17 (23.0)                      7 (22.6)                     0.965            6 (28.6)                  2 (33.3)                 1.000
   Height, cm                               170 \[165-175\]                170 \[165-175\]              0.816            172 \[170-176\]           173 \[163-177\]          0.716
   Weight, kg                               65 \[58-77\]                   65 \[60-75\]                 0.737            68 \[62-74\]              66 \[63-69\]             0.533
   BMI, kg/m^2^                             22.9 \[20.4-26.1\]             22.2 \[21.7-24.4\]           0.645            22.3 \[21.5-23.8\]        23.3 \[22.0-24.3\]       0.971
   BSA, m^2^                                1.76 \[1.63-1.91\]             1.77 \[1.65-1.91\]           0.778            1.81 \[1.72-1.92\]        1.81 \[1.69-1.84\]       0.619
  *Background medical status*                                                                                                                                                
   Hypertension, n                          4 (5.4)                        2 (6.5)                      0.802            0 (0.0)                   1 (16.7)                 0.222
   Diabetes mellitus, n                     9 (12.2)                       6 (19.4)                     0.512            4 (19.0)                  2 (33.3)                 0.588
   Smoking, n                               16 (21.6)                      9 (29.0)                     0.416            6 (28.6)                  2 (33.3)                 1.000
   Alcoholic liver cirrhosis, n             5 (6.8)                        1 (3.2)                      0.802            1 (4.8)                   1 (16.7)                 0.402
   HBV hepatitis, n                         52 (70.3)                      22 (71.0)                    0.943            12 (57.1)                 4 (66.6)                 1.000
   HCV hepatitis, n                         7 (9.5)                        2 (6.5)                      0.904            2 (9.5)                   1 (16.7)                 0.545
   Liver tumor, n                           31 (41.9)                      6 (19.4)                     0.027            6 (28.6)                  0 (0.0)                  0.284
   Cholestatic disease, n                   6 (8.1)                        5 (16.1)                     0.382            2 (9.5)                   0 (0.0)                  1.000
   Hepatic encephalopathy, n                12 (16.2)                      10 (32.3)                    0.065            2 (9.5)                   1 (16.7)                 0.545
   Serum albumin level, g/L                 31.5 \[27.5-36.0\]             30.0 \[25.5-32.4\]           0.122            36.1 \[31.5-38.1\]        32.7 \[27.8-37.8\]       0.585
   Total bilirubin, *μ*mol/L                33.7 \[20.1-75.5\]             78.1 \[39.3-273.9\]          0.003            39.7 \[21.9-99.7\]        136.3 \[103.5-191.4\]    0.031
   Prothrombin time, s                      18.6 \[15.7-25.1\]             21.4 \[18.3-25.7\]           0.152            17.0 \[15.3-19.4\]        25.1 \[22.3-28.3\]       0.010
   MELD score                               12.6 \[9.1-20.9\]              17.8 \[12.6-21.8\]           0.015            13.2 \[9.4-18.6\]         21.5 \[20.4-24.9\]       0.031
   CTP score                                9 \[7-11\]                     10 \[10-11\]                 0.003            8 \[6-9\]                 10 \[10-11\]             0.012
   Child class, n (A/ B/ C)                 16/24/34                       1/8/22                       0.020            7/9/5                     0/0/6                    0.003
  *Baseline renal function*                                                                                                                                                  
   Preoperative serum creatinin, *μ*mol/L   62.0 \[52.3-74.8\]             65.0 \[54.0-78.5\]           0.421            61.0 \[53.0-95.0\]        56.0 \[51.3-57.8\]       0.122
   Preoperative estimated                   129.6                          118.5                        0.369            108.8                     154.6                    0.092
   GFR, ml/min/1.73 m^2^                    \[105.0-161.7\]                \[98.9-147.7\]               \[78.4-152.6\]   \[139.7-172.7\]                                    
   Preoperative blood urea                  5.20                           4.80                         0.464            5.94                      3.75                     0.216
   nitrogen, mmol/L                         \[4.00-7.17\]                  \[4.10-6.29\]                \[4.83-6.50\]    \[3.01-5.66\]                                      
  *Donor liver factors*                                                                                                                                                     
   Warm ischemic time, s                    180 \[150-180\]                180 \[150-195\]              0.623            270 \[180-300\]           300 \[210-300\]          0.630
   Cold ischemic time, min                  493 \[413-554\]                540 \[445-647\]              0.028            440 \[385-510\]           418 \[385-540\]          0.883
  *Operation and anesthesia details*                                                                                                                                        
   Operation time, min                      533 \[480-600\]                590 \[530-678\]              0.015            540 \[480-600\]           570 \[518-690\]          0.357
   Anhepatic phase, min                     103 \[90-116\]                 112 \[107-136\]              0.002            80 \[75-92\]              95 \[92-103\]            0.152
   Norepinephrine use, n                    6 (8.1)                        4 (12.9)                     0.690            1 (4.8)                   0 (0.0)                  1.000
   pRBC transfusion, mL                     2800 \[1275-4400\]             4800 \[2200-6450\]           0.005            3200 \[2000-4800\]        4800 \[2650-7400\]       0.255
   FFP transfusion, mL                      1000 \[600-1950\]              1400 \[900-2700\]            0.066            1200 \[550-2000\]         2650 \[1150-4000\]       0.129
   Platelet transfusion, units              0 \[0-0\]                      0 \[0-0\]                    0.357            0 \[0-1\]                 0 \[0-2\]                0.857
   Cryoprecipitate transfusion, units       0 \[0-10\]                     10 \[0-10\]                  0.035            0 \[0-20\]                15 \[3-20\]              0.378
   PVF, mL/min                              1730 \[1385-2237\]             1444 \[1068-1898\]           0.015            1670 \[1200-2400\]        1122 \[1023-1183\]       0.036
   PVF/height, mL/min/cm                    10.12 \[8.35-13.22\]           8.11 \[6.33-10.76\]          0.012            9.82 \[7.26-13.34\]       6.575 \[6.06-7.04\]      0.026
   PVF/weight, mL/min/kg                    27.59 \[20.26-34.92\]          20.23 \[17.45-28.50\]        0.013            26.94 \[20.40-33.75\]     16.86 \[15.48-18.16\]    0.026
   PVF/BMI, m^2^·mL/min/kg                  76.72 \[58.29-104.11\]         61.94 \[48.33-77.44\]        0.018            77.86 \[58.54-103.36\]    47.66 \[42.70-53.52\]    0.036
   PVF/BSA, mL/min/m^2^                     1000.0 \[779.2-1243.4\]        788.0 \[643.1-1029.2\]       0.009            970.9 \[734.3-1279.9\]    627.7 \[588.4-681.2\]    0.015
   HAF, mL/min                              149.0 \[106.8-214.5\]          165.0 \[106.2-215.5\]        0.905            226.0 \[142.0-280.0\]     167.0 \[113.4-214.6\]    0.431
   HAF/height, mL/min/cm                    0.86 \[0.62-1.24\]             0.98 \[0.61-1.23\]           0.905            1.28 \[0.81-1.60\]        0.94 \[0.70-1.20\]       0.254
   HAF/weight, mL/min/kg                    2.20 \[1.63-3.22\]             2.49 \[1.47-3.12\]           0.886            3.21 \[2.26-4.31\]        2.47 \[1.76-3.09\]       0.408
   HAF/BMI, m^2^·mL/min/kg                  6.38 \[4.50-8.88\]             7.00 \[4.07-9.62\]           0.855            9.39 \[5.96-12.74\]       7.57 \[4.67-10.13\]      0.196
   HAF/BSA, mL/min/m^2^                     83.38 \[58.27-122.63\]         96.13 \[54.88-116.29\]       0.902            134.64 \[74.47-153.37\]   91.16 \[66.86-114.27\]   0.260
   HBI, mL/min                              1899 \[1570-2457\]             1656 \[1215-2082\]           0.015            2170 \[1480-2575\]        1260 \[1224-1318\]       0.042
   HBI/height, mL/min/cm                    11.32 \[9.43-14.32\]           9.30 \[7.23-11.99\]          0.010            12.76 \[9.22-14.97\]      7.62 \[7.39-7.80\]       0.036
   HBI/weight, mL/min/kg                    30.05 \[22.00-38.91\]          24.01 \[19.33-31.79\]        0.014            29.63 \[23.77-36.68\]     19.61 \[18.71-20.20\]    0.049
   HBI/BMI, m^2^·mL/min/kg                  86.84 \[63.64-111.89\]         68.71 \[51.98-88.65\]        0.014            94.36 \[68.69-111.31\]    54.67 \[49.78-58.68\]    0.044
   HBI/BSA, mL/min/m^2^                     1098.6 \[895.2-1377.7\]        850.0 \[702.8-1158.1\]       0.006            1207.3 \[858.9-1418.1\]   731.1 \[705.9-762.8\]    0.036
   Urine volume, mL                         1300 \[800-2000\]              1300 \[725-1725\]            0.621            1300 \[750-2000\]         1000 \[650-1180\]        0.515
  *Postoperative factors*                                                                                                                                                    
   Tacrolimus use, n                        71 (95.9)                      31 (100.0)                   0.553            20 (95.2)                 6 (100.0)                1.000
   Cyclosporine use, n                      3 (4.1)                        0 (0.0)                      0.553            1 (4.8)                   0 (0.0)                  1.000

BMI = body-mass index; BSA = body surface area; MELD = model for end-stage liver disease; CTP = Child-Turcotte-Pugh; GFR = glomerular filtration rate; pRBC = packed red blood cells; FFP = fresh frozen plasma; PVF = intraoperative mean portal vein flow; HAF = intraoperative mean hepatic artery flow; HBI = intraoperative mean hepatic blood inflow; Warm ischemic time: from no heartbeat to cold perfusion; Cold ischemic time: from cold perfusion to liver blood supply restored.

###### 

Prediction model.

  ---------------------------------------------------------------------------------------------------------------------------------------------
                Variables from LASSO\     Model A\            Model B\                                                                
                regression (lambda.1se)   (LASSO variables)   (Simplified)                                                            
  ------------- ------------------------- ------------------- -------------- ------- ------------- --------- ------- ---------------- ---------
  *Variable*    Coef                      95%CI               p-value        Coef    95%Cl         p-value   Coef    95%Cl            p-value

   CTP score    0.32                      (0.12, 0.55)        0.003          0.29    0.05, 0.56    0.022     0.26    (0.03, 0.52)     0.033

   CIT / 100    0.45                      (0.10, 0.83)        0.015          0.30    -0.16, 0.78   0.211                               

   AP /10       0.30                      (0.12, 0.50)        0.002          0.16    -0.07, 0.41   0.185     0.27    (0.07, 0.50)     0.014

   HBI / h      -0.17                     (-0.30, -0.05)      0.008          -0.28   -0.47,-0.13   0.001     -0.26   (-0.45, -0.11)   0.002

   OT / 100     0.58                      (0.19, 1.01)        0.005          0.37    -0.18, 0.99   0.212                               

   pRBC /1000   0.20                      (0.07, 0.35)        0.005          0.19    0.01, 0.39    0.051     0.21    (0.03, 0.40)     0.027

  *AIC*                                                       101.54                               101.84                             
  ---------------------------------------------------------------------------------------------------------------------------------------------

###### 

Hosmer and Lemeshow goodness of fit (GOF) test.

  *Model*   *Hosmer and Lemeshow goodness of fit (GOF) test*       
  --------- -------------------------------------------------- --- -------
  Model A   8.068                                              8   0.427
  Model B   5.473                                              8   0.706

###### 

The C-index of the models.

  ----------------------------------------------------------------
  Model                Development cohort    Validation cohort
  -------------------- --------------------- ---------------------
  Model A              0.847 (0.765-0.928)   0.921 (0.809-1.000)

  Model B              0.823 (0.738-0.908)   0.921 (0.816-1.000)

  Comparison of AUC\   0.167                 1.000
  (p-value)                                  
  ----------------------------------------------------------------

[^1]: Academic Editor: Haruki Komatsu
